ORMP — Oramed Pharmaceuticals Inc.
Healthcare • Biotechnology
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its...…
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Price
Showing 1Y history. Source: FMP historical price full.
- Prev Close
- $2.69
- Day High
- $2.77
- Day Low
- $2.66
- 52w High
- $3.09
- 52w Low
- $1.82
- Volume
- 30,660
- Avg Volume
- Beta
- 1.169
* TTM/most recent where available
Company
- Ticker
- ORMP
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Nadav Kidron
- Employees
- 13
- Website
- www.oramed.com
Key Metrics
- Market Cap
- 114M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).